Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caris Life SciencesCAI -3.22%12 EV-to-EBIT is 39.40 as of Aug. 12, 2026. GuruFocus rates CAI with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 367 Biotechnology companies, Caris Life Sciences ranks worse than 77.11% on this metric.
Caris Life Sciences (NAS:CAI) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Caris Life Sciences's Enterprise Value for the quarter that ended in Jun. 2026 was $4,700.4 Mil.
Caris Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $151.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caris Life Sciences EV-to-EBIT Related Terms
Caris Life Sciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Caris Life Sciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Caris Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caris Life Sciences EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caris Life Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Caris Life Sciences's EV-to-EBIT falls into.
Caris Life Sciences's current Enterprise Value is $5,985.2 Mil.
Caris Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $151.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caris Life Sciences (CAI) has a EV-to-EBIT of 39.40 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Caris Life Sciences and its competitors. According to the industry distribution chart, Caris Life Sciences ranks #283 out of 367 companies in the Biotechnology industry, placing it in the top 77.1%.
Is Caris Life Sciences' EV-to-EBIT too high?
Caris Life Sciences' current EV-to-EBIT is 39.40. The Biotechnology industry median EV-to-EBIT is 15.96. Caris Life Sciences' value of 39.40 is 146.9% above this industry median. Based on the distribution chart, Caris Life Sciences ranks #283 out of 367 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Caris Life Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Caris Life Sciences' EV-to-EBIT compare to EWTX and TNGX?
According to the Biotechnology industry distribution chart, Caris Life Sciences ranks #283 out of 367 companies for EV-to-EBIT. This places Caris Life Sciences in the lower half of its industry. The industry median EV-to-EBIT is 15.96. Caris Life Sciences' value of 39.40 is 146.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.96, based on 367 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caris Life Sciences's current EV-to-EBIT of 39.40 is 146.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Caris Life Sciences and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caris Life Sciences's current EV-to-EBIT is 39.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caris Life Sciences stock overvalued right now?
Caris Life Sciences (CAI) has a current EV-to-EBIT of 39.40. The current EV-to-EBIT is 39.40 and 146.9% above the Biotechnology industry median of 15.96. Caris Life Sciences' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Caris Life Sciences (CAI), the current EV-to-EBIT is 39.40 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
12GF Score
Get the complete analysis for CAI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI has been successfully added to your 
